相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials
Jack D. Schim et al.
HEADACHE (2022)
Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
Rami Apelian et al.
JOURNAL OF HEADACHE AND PAIN (2022)
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial
Messoud Ashina et al.
LANCET NEUROLOGY (2022)
Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
David Kudrow et al.
BMC NEUROLOGY (2021)
Diagnosis and management of migraine in ten steps
Anna K. Eigenbrodt et al.
NATURE REVIEWS NEUROLOGY (2021)
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina et al.
CEPHALALGIA (2020)
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B. Lipton et al.
NEUROLOGY (2020)
Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis
Raeburn B. Forbes et al.
HEADACHE (2020)
European headache federation consensus on the definition of resistant and refractory migraine Developed with the endorsement of the European Migraine & Headache Alliance (EMHA)
Simona Sacco et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study
Stephen Silberstein et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
David W. Dodick et al.
HEADACHE (2020)
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine
Brian Baker et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials
Stephen D. Silberstein et al.
HEADACHE (2019)
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Vladimir Skljarevski et al.
CEPHALALGIA (2018)
Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults
Cristina Tassorelli et al.
CEPHALALGIA (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design
Daniel Serrano et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
Andrew M. Blumenfeld et al.
HEADACHE (2013)
Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults
S. Silberstein et al.
CEPHALALGIA (2008)
分享论文
